Nkarta, Inc. Stock Price, News & Analysis

Nkarta (NKTX) announced the appointment of Shawn Rose, M.D. Ph.D., as Chief Medical Officer and Head of R&D, effective June 23, 2025. Dr. Rose, who brings extensive experience in immunology and drug development, replaces David R. Shook, M.D. Dr. Rose previously served as Chief Development Officer at Vividion Therapeutics and has contributed to developing approved medicines like Sotyktu, Stelara, and Tremfya. His appointment aligns with Nkarta's strategic focus on using their NK cell platform to treat autoimmune diseases. Dr. Rose's background includes leadership roles at Magenta Therapeutics, Annexon Biosciences, Janssen Pharmaceuticals, and Bristol-Myers Squibb. Dr. Shook will remain as a consultant through July 11 before pursuing opportunities in oncology.

Nkarta (NKTX) reported its Q1 2025 financial results and corporate updates. The company holds a strong cash position of $351.9 million, expected to fund operations into 2029. Key highlights include ongoing enrollment in multiple clinical trials for NKX019, including the Ntrust-1 trial (expanded to include primary membranous nephropathy), Ntrust-2 trial, and investigator-sponsored trials for myasthenia gravis and systemic lupus erythematosus. The company modified its lymphodepletion regimen across platforms to include both fludarabine and cyclophosphamide. Initial clinical data from Ntrust trials is expected in H2 2025. Financially, Nkarta reported a Q1 net loss of $32.0 million ($0.43 per share) and implemented a restructuring plan reducing workforce by 34% to extend cash runway.

Nkarta (Nasdaq: NKTX), a biopharmaceutical company specializing in engineered natural killer (NK) cell therapies, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference.

The company will engage in a fireside chat scheduled for April 8, 2025, at 11:00 a.m. ET. Investors and interested parties can access a live webcast of the event through the Investors section of Nkarta's website. The presentation recording will remain available on www.nkartatx.com for approximately 90 days following the event.

Nkarta (NKTX) reported its Q4 and full year 2024 financial results, announcing a significant restructuring including a 34% workforce reduction (53 positions) to extend cash runway. The company ended 2024 with a cash balance of $380.5 million, now expected to fund operations into 2029.

For FY2024, Nkarta reported a net loss of $108.8 million ($1.60 per share), with R&D expenses of $96.7 million and G&A expenses of $31.5 million. The restructuring is expected to cost $5.5-6.5 million in cash payments.

The company's development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in autoimmune conditions. Initial data from the Ntrust-1 and Ntrust-2 trials is expected in H2 2025. The executive leadership team will be reduced by over 50% as part of the restructuring efforts.

Nkarta (Nasdaq: NKTX), a biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies, has announced its upcoming participation in two major investor conferences in March 2025.

The company will be featured in fireside chat sessions at the:

• TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 3:10 p.m. ET
• Leerink Partners 2025 Global Healthcare Conference on March 10, 2025, at 3:00 p.m. ET

Investors and interested parties can access simultaneous webcasts of both events through Nkarta's website at www.nkartatx.com. Recordings will remain available on the company's Investors section for approximately 90 days after the events.

Nkarta (NKTX) announced the opening of enrollment for Ntrust-2 and IND clearance for an investigator-sponsored trial (IST) evaluating NKX019, their allogeneic CD19-directed CAR NK-cell therapy. Ntrust-2 will evaluate the treatment across three parallel cohorts: systemic sclerosis, myositis, and ANCA-associated vasculitis. The IST will study NKX019 in myasthenia gravis patients.

The treatment protocol involves administering NKX019 on Days 0, 3, and 7 following lymphodepletion with cyclophosphamide. The therapy aims to provide a safe, accessible treatment option for autoimmune diseases through B-cell depletion, potentially enabling long-term remissions via immune system reset.

Patient dosing has begun in both Ntrust-1 and the IST for systemic lupus erythematosus, with preliminary data from Ntrust-1 and Ntrust-2 expected in 2025.

Nkarta (Nasdaq: NKTX), a biopharmaceutical company focused on engineered natural killer (NK) cell therapies, has announced its upcoming participation in the 7th Annual Evercore HealthCONx Conference. The company will participate in a fireside chat scheduled for December 4, 2024, at 2:10 p.m. ET.

The event will be accessible through a live webcast on Nkarta's website investor section, with a replay available for approximately 90 days following the presentation.

Nkarta (Nasdaq: NKTX), a company focused on engineered natural killer (NK) cell therapies, has announced its upcoming participation in the Stifel 2024 Healthcare Conference. The company will participate in a fireside chat scheduled for November 19, 2024, at 10:55 a.m. ET. The event will be webcast live on Nkarta's website investor section, with a replay available for approximately 90 days afterward.

Nkarta (NKTX) reported Q3 2024 financial results and corporate updates. The company has initiated patient dosing in both Ntrust-1 and investigator-sponsored trials of NKX019 for autoimmune diseases. Cash position stands at $405.3 million, expected to fund operations into late 2027. The company reported a net loss of $28.3 million ($0.39 per share) for Q3. Notably, Nkarta has decided to discontinue NKX019 development in lymphoma to focus on autoimmune diseases. Preliminary clinical data from Ntrust-1 and Ntrust-2 trials is planned for 2025.